Cytokines are signaling molecules—soluble proteins secreted by immune cells—that coordinate immune responses by allowing distant cells to communicate. These chemical messengers can induce inflammation, suppress inflammation, promote cell proliferation, or trigger cell death. Dysregulation of cytokine production underlies much of pathology in inflammatory and autoimmune diseases.
TNF-α (tumor necrosis factor-alpha) is the prototypical pro-inflammatory cytokine, often called the "master inflammatory cytokine." Produced primarily by activated macrophages, TNF-α binds to TNF receptors on endothelial cells, increasing vascular permeability and allowing immune cells to extravasate into tissues. It stimulates other cells to produce additional pro-inflammatory cytokines, creating a cascade. It promotes the expression of adhesion molecules and chemokines that recruit immune cells to inflammatory sites. While essential for controlling infection, excessive TNF-α drives rheumatoid arthritis and inflammatory bowel disease—explaining why TNF-blocking biologics (infliximab, etanercept) are among medicine's most successful anti-inflammatory therapies.
IL-1β (interleukin-1 beta) is another key pro-inflammatory cytokine, produced by macrophages and dendritic cells. It induces fever, promotes vasodilation, and drives IL-6 production. IL-1β also drives T cell activation and differentiation toward Th17 cells. Notably, IL-1β is produced as an inactive precursor requiring processing by the NLRP3 inflammasome—a protein complex activated by damage signals or microbial patterns. This two-step process prevents inappropriate IL-1β production.
IL-6 serves multiple roles depending on context. In acute responses, IL-6 promotes acute phase reactant production by the liver and coordinates fever. However, chronic IL-6 signaling drives persistent inflammation. IL-6 is also produced by gut bacteria indirectly through their metabolites and directly by intestinal epithelial cells responding to bacterial signals. Elevated fecal and systemic IL-6 associates with inflammatory bowel disease, suggesting dysbiotic microbiota patterns drive excessive IL-6 production.
IL-10 is a cardinal anti-inflammatory cytokine, produced by regulatory T cells, some macrophages, and B cells. IL-10 suppresses TNF-α, IL-1β, and IL-6 production and drives alternative macrophage activation toward tissue-remodeling phenotypes. IL-10 is essential for immune tolerance—mutations impairing IL-10 signaling cause early-onset inflammatory bowel disease, highlighting its critical role in preventing dysbiosis-driven inflammation.
IL-17 (interleukin-17, mostly from Th17 cells) promotes mucosal barrier function by inducing antimicrobial peptides and mucus production. It recruits neutrophils and promotes IL-1β and TNF-α production. This cytokine is essential for defense against extracellular bacteria and fungi but becomes pathogenic in excess, driving inflammatory arthritis and autoimmune diseases. Notably, Th17 differentiation requires IL-6 and TGF-β, and the Th17/Treg balance is profoundly shaped by the microbiota—SCFAs like butyrate promote Tregs while segmented filamentous bacteria promote Th17 in mice.
IFN-γ (interferon-gamma) is the prototypical Th1 cytokine, essential for antiviral and intracellular bacterial immunity. Produced by CD8+ T cells and Th1 cells, IFN-γ activates macrophages to kill intracellular pathogens and promotes MHC class I and II expression, enhancing antigen presentation. However, excessive IFN-γ drives autoimmunity—explaining why IFN-γ elevation associates with multiple sclerosis and type 1 diabetes.
TGF-β (transforming growth factor-beta) is the prototypical immunosuppressive cytokine, essential for generating regulatory T cells (Tregs). TGF-β signaling in CD4+ T cells, combined with IL-2, drives Foxp3 expression and Treg differentiation. TGF-β also suppresses effector T cell and B cell responses. In the context of IL-6, however, TGF-β drives Th17 instead of Treg differentiation—illustrating how cytokine combinations determine outcomes.
Cytokine storms—massive simultaneous elevation of multiple pro-inflammatory cytokines—occur in severe infections and sepsis, causing tissue damage, endothelial barrier breakdown, and potentially fatal shock. COVID-19 severity associates with exaggerated TNF-α, IL-6, and IL-1β production, illustrating how immune dysregulation can exceed the threat's severity.
Critically, the microbiome shapes systemic cytokine production through multiple mechanisms. Bacterial metabolites like butyrate enhance IL-10 and Treg production while suppressing IL-17. LPS from gram-negative bacteria activates TLR4, driving TNF-α and IL-6. Segmented filamentous bacteria promote Th17 cells and IL-17 production. Dysbiotic microbiota patterns shift the balance toward pro-inflammatory cytokines, contributing to inflammatory bowel disease, obesity-associated inflammation, and systemic inflammation in aging.